Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11076 clinical trials
Efficacy of Near-Infrared Vein Imaging for Difficult IV Placement

The objective of this project is to define the effectiveness and therefore the role of NIR vein finders in adult patients with difficult peripheral venous access. The specific objective of the proposed randomized controlled trial is to test the clinical success rate of placing peripheral venous catheters in 'difficult' access …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Lap-assisted vs. US-Guided Visualization of TAP Blocks

Peripheral nerve blocks have been effective in decreasing post-operative pain as well as the use of narcotics for numerous years. Typically, these blocks are placed by anesthesiologist via ultrasound. In more recent years, surgeons have been placing nerve blocks laparoscopically. Since there are few studies that looks compare the two …

nerve blocks
nerve block
narcotics
postoperative pain
laparoscopic surgery
  • 0 views
  • 19 Feb, 2024
  • 1 location
Topotecan Episcleral Plaque for Treatment of Retinoblastoma

This single site, single-arm, non-randomized, dose escalation phase I toxicity clinical trial will assess primarily the safety and secondarily the efficacy of episcleral topotecan in patients with active residual or recurrent intraocular retinoblastoma in at least one eye following completion of first-line therapy.

brachytherapy
platelet count
intraocular retinoblastoma
renal function
topotecan
  • 0 views
  • 19 Feb, 2024
  • 1 location
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Background People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see if these drugs …

antineoplastic agents
pancreatic neuroendocrine tumor
solid neoplasm
mucinous cystadenocarcinoma
ovarian cancer
  • 0 views
  • 19 Feb, 2024
  • 1 location
Venglustat in Combination With Cerezyme in Adult and Pediatric Patients With Gaucher Disease Type 3

Cohort 3 Evaluate the efficacy of venglustat in combination with Cerezyme in adult and pediatric GD3 patients by assessing: CSF Lyso-GL1 levels Modified Friedreichs Ataxia Rating Scale - Activities of Daily Living (FARS-ADL) Brain resting-state functional Magnetic Resonance Imaging (rs-fMRI) reflecting connectivity between parieto-occipital areas Bone disease manifestations Evaluate safety …

  • 0 views
  • 19 Feb, 2024
  • 7 locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

factor ix
fitusiran
antihemophilic factor
bethesda assay
haemophilia a
  • 0 views
  • 19 Feb, 2024
  • 11 locations
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants  

To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4) To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of …

  • 0 views
  • 19 Feb, 2024
  • 32 locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

factor ix
fitusiran
antihemophilic factor
bethesda assay
haemophilia a
  • 0 views
  • 19 Feb, 2024
  • 11 locations
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

To describe the antibody responses against the antigens of the routine pediatric vaccines administered in a 3-dose series concomitantly with MenACYW conjugate vaccine or a licensed meningococcal vaccine. To describe the safety profile of MenACYW conjugate vaccine and a licensed meningococcal vaccine.

diabetes
meningococcal conjugate
dtap
diphtheria
genetic diseases
  • 0 views
  • 19 Feb, 2024
  • 29 locations
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

To describe the antibody responses against the antigens of the routine pediatric vaccines administered in a 3-dose series concomitantly with MenACYW conjugate vaccine or a licensed meningococcal vaccine. To describe the safety profile of MenACYW conjugate vaccine and a licensed meningococcal vaccine.

diabetes
meningococcal conjugate
dtap
diphtheria
genetic diseases
  • 0 views
  • 19 Feb, 2024
  • 29 locations